Yang Yang, Zhang Yingshi, Chen Lixin, Li Ze, Zhao Qingchun
School of Life Sciences and Biopharmaceuticals, Shenyang Pharmaceutical University, Shenyang, Liaoning, China.
Department of Pharmacy, Jinqiu Hospital of Liaoning Province, Shenyang, Liaoning, China.
Front Pharmacol. 2025 Jul 8;16:1598053. doi: 10.3389/fphar.2025.1598053. eCollection 2025.
BACKGROUND: Depression is a common and severe mental disorder. Quercetin, a natural flavonoid compound, has been shown in several studies through animal experiments to improve depressive symptoms, demonstrating significant antidepressant potential. OBJECTIVE: This study represents the first preclinical meta-analysis on quercetin and depression, aiming to systematically evaluate the antidepressant effects of quercetin in animal studies. Methods: This study conducted a systematic search of the PubMed, EMBASE, Cochrane Library, and Web of Science electronic databases, with the search period covering from the inception of the databases to January 2025. Subsequently, the SYRCLE risk of bias assessment tool was used for quality evaluation, and data analysis was performed using RevMan 5.4 software. RESULTS: This systematic review included 52 animal studies for random-effects meta-analysis. The results indicated that, compared to the control group, quercetin significantly reduced the immobility time in the forced swimming test and tail suspension test, as well as the time spent in the closed arms of the elevated plus maze. Simultaneously, it increased sucrose preference, swimming time in the forced swimming test, total distance traveled in the open field test, time spent in the central area, and the number of entries into the central area. In the elevated plus maze test, quercetin also increased the time spent in the open arms and the number of entries into the open arms. However, it did not produce a significant effect on the number of standing episodes in the open field test. Moreover, quercetin increased the levels of glutathione (GSH), superoxide dismutase (SOD), catalase (CAT), and brain-derived neurotrophic factor (BDNF), while reducing the levels of malondialdehyde (MDA), tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), interleukin-6 (IL-6), and corticosterone (CORT). CONCLUSION: This meta-analysis indicates that quercetin significantly improves depressive symptoms. However, further high-quality studies are needed to explore the role of quercetin in antidepressant research. SYSTEMATIC REVIEW REGISTRATION: http://inplasy.com/, Identifier: INPLASY202530047.
背景：抑郁症是一种常见且严重的精神障碍。槲皮素是一种天然黄酮类化合物，多项动物实验研究表明其可改善抑郁症状，具有显著的抗抑郁潜力。 目的：本研究是关于槲皮素与抑郁症的首个临床前荟萃分析，旨在系统评价槲皮素在动物研究中的抗抑郁作用。方法：本研究对PubMed、EMBASE、Cochrane图书馆和Web of Science电子数据库进行了系统检索，检索期从数据库建立至2025年1月。随后，使用SYRCLE偏倚风险评估工具进行质量评估，并使用RevMan 5.4软件进行数据分析。 结果：本系统评价纳入52项动物研究进行随机效应荟萃分析。结果表明，与对照组相比，槲皮素显著缩短了强迫游泳试验和悬尾试验中的不动时间，以及高架十字迷宫封闭臂中的停留时间。同时，它增加了蔗糖偏好、强迫游泳试验中的游泳时间、旷场试验中的总行进距离、在中央区域的停留时间以及进入中央区域的次数。在高架十字迷宫试验中，槲皮素还增加了在开放臂中的停留时间和进入开放臂的次数。然而，它对旷场试验中的站立次数没有显著影响。此外，槲皮素增加了谷胱甘肽（GSH）、超氧化物歧化酶（SOD）、过氧化氢酶（CAT）和脑源性神经营养因子（BDNF）的水平，同时降低了丙二醛（MDA）、肿瘤坏死因子-α（TNF-α）、白细胞介素-1β（IL-1β）、白细胞介素-6（IL-6）和皮质酮（CORT）的水平。 结论：本荟萃分析表明槲皮素可显著改善抑郁症状。然而，需要进一步的高质量研究来探索槲皮素在抗抑郁研究中的作用。 系统评价注册：http://inplasy.com/，标识符：INPLASY202530047。
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2020-1-9
Cochrane Database Syst Rev. 2004
Health Technol Assess. 2024-10
Health Technol Assess. 2001
Cochrane Database Syst Rev. 2017-12-22
Psychopharmacol Bull. 2024-7-8
World J Biol Psychiatry. 2024-12
Inflammopharmacology. 2024-12
Zotero 插件
